Curcuminoids modify lipid profile in type 2 diabetes mellitus: A randomized controlled trial.
暂无分享,去创建一个
Yunes Panahi | Amirhossein Sahebkar | A. Sahebkar | Ž. Reiner | Y. Panahi | M. Majeed | N. Khalili | Željko Reiner | S. Namazi | Soha Namazi | Ebrahim Sahebi | Muhammed Majeed | Nahid Khalili | E. Sahebi
[1] Y. Panahi,et al. Investigation of the Efficacy of Adjunctive Therapy with Bioavailability‐Boosted Curcuminoids in Major Depressive Disorder , 2015, Phytotherapy research : PTR.
[2] A. Sahebkar,et al. Comparison of the effects of fibrates versus statins on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of head-to-head randomized controlled trials , 2017, BMC Medicine.
[3] R. DiSilvestro,et al. Diverse effects of a low dose supplement of lipidated curcumin in healthy middle aged people , 2012, Nutrition Journal.
[4] M. Banach,et al. Raloxifene Lowers Plasma Lipoprotein(a) Concentrations: a Systematic Review and Meta-analysis of Randomized Placebo-Controlled Trials , 2017, Cardiovascular Drugs and Therapy.
[5] M. Majeed,et al. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. , 1998, Planta medica.
[6] A. Sahebkar,et al. Curcumin as a natural regulator of monocyte chemoattractant protein-1. , 2017, Cytokine & growth factor reviews.
[7] Biao Xu,et al. Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials , 2015, BMC Medicine.
[8] A. Sahebkar,et al. Preventing cardiovascular heart disease: Promising nutraceutical and non-nutraceutical treatments for cholesterol management. , 2017, Pharmacological research.
[9] A. Sahebkar,et al. Curcumin and Endothelial Function: Evidence and Mechanisms of Protective Effects. , 2017, Current pharmaceutical design.
[10] Y. Panahi,et al. Curcumin as a potential candidate for treating hyperlipidemia: A review of cellular and metabolic mechanisms , 2018, Journal of cellular physiology.
[11] A. Sahebkar,et al. Lipid-modifying effects of nutraceuticals: An evidence-based approach. , 2016, Nutrition.
[12] J. Zamorano,et al. A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy. , 2015, Atherosclerosis. Supplements.
[13] A. Sahebkar,et al. Supplementation with coenzyme Q10 reduces plasma lipoprotein(a) concentrations but not other lipid indices: A systematic review and meta-analysis. , 2016, Pharmacological research.
[14] A. Kontush,et al. HDL particle subpopulations: Focus on biological function , 2015, BioFactors.
[15] A. Sahebkar. Are Curcuminoids Effective C‐Reactive Protein‐Lowering Agents in Clinical Practice? Evidence from a Meta‐Analysis , 2014, Phytotherapy research : PTR.
[16] Y. Panahi,et al. Lipid-modifying effects of adjunctive therapy with curcuminoids-piperine combination in patients with metabolic syndrome: results of a randomized controlled trial. , 2014, Complementary therapies in medicine.
[17] A. Sahebkar,et al. Curcumin: A new candidate for melanoma therapy? , 2016, International journal of cancer.
[18] Y. Panahi,et al. Curcumin Lowers Serum Lipids and Uric Acid in Subjects With Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial , 2016, Journal of cardiovascular pharmacology.
[19] A. Sahebkar,et al. Curcumin downregulates human tumor necrosis factor-α levels: A systematic review and meta-analysis ofrandomized controlled trials. , 2016, Pharmacological research.
[20] A. Sahebkar,et al. Curcumin: An Effective Inhibitor of Interleukin-6. , 2017, Current pharmaceutical design.
[21] S. Asgary,et al. Treatment of Non‐alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo‐controlled Trial , 2016, Phytotherapy research : PTR.
[22] J. Borén,et al. Lipoprotein(a) as a cardiovascular risk factor: current status , 2010, European heart journal.
[23] Jennifer G. Robinson,et al. Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data. , 2016, The lancet. Diabetes & endocrinology.
[24] G. Ferns,et al. Effects of Supplementation with Curcuminoids on Dyslipidemia in Obese Patients: A Randomized Crossover Trial , 2013, Phytotherapy research : PTR.
[25] S. Bo,et al. Effect of curcumin on circulating interleukin-6 concentrations: A systematic review and meta-analysis of randomized controlled trials. , 2016, Pharmacological research.
[26] Ž. Reiner. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update. , 2013, Nutrition, metabolism, and cardiovascular diseases : NMCD.
[27] Sarah Parish,et al. Effects of extended-release niacin with laropiprant in high-risk patients. , 2014, The New England journal of medicine.
[28] S. Jirawatnotai,et al. Curcumin Extract for Prevention of Type 2 Diabetes , 2012, Diabetes Care.
[29] A. Sahebkar. Curcuminoids for the management of hypertriglyceridaemia , 2014, Nature Reviews Cardiology.
[30] G. Ferns,et al. Investigation of the Effects of Curcumin on Serum Cytokines in Obese Individuals: A Randomized Controlled Trial , 2014, TheScientificWorldJournal.
[31] M. Amiri,et al. Improvement of sulphur mustard-induced chronic pruritus, quality of life and antioxidant status by curcumin: results of a randomised, double-blind, placebo-controlled trial , 2011, British Journal of Nutrition.
[32] Y. Panahi,et al. Mitigation of Systemic Oxidative Stress by Curcuminoids in Osteoarthritis: Results of a Randomized Controlled Trial , 2016, Journal of dietary supplements.
[33] M. Ghanei,et al. Effects of Curcuminoids-Piperine Combination on Systemic Oxidative Stress, Clinical Symptoms and Quality of Life in Subjects with Chronic Pulmonary Complications Due to Sulfur Mustard: A Randomized Controlled Trial , 2016, Journal of dietary supplements.
[34] A. Sahebkar,et al. Impact of L-carnitine on plasma lipoprotein(a) concentrations: A systematic review and meta-analysis of randomized controlled trials , 2016, Scientific Reports.
[35] A. Sahebkar,et al. Analgesic Efficacy and Safety of Curcuminoids in Clinical Practice: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. , 2015, Pain medicine.
[36] A. Sahebkar,et al. Is There a Role for Curcumin Supplementation in the Treatment of Non-Alcoholic Fatty Liver Disease? The Data Suggest Yes. , 2017, Current pharmaceutical design.
[37] A. Sahebkar. Why it is necessary to translate curcumin into clinical practice for the prevention and treatment of metabolic syndrome? , 2013, BioFactors.
[38] Y. Panahi,et al. Antioxidant and anti-inflammatory effects of curcuminoid-piperine combination in subjects with metabolic syndrome: A randomized controlled trial and an updated meta-analysis. , 2015, Clinical nutrition.
[39] A. Colletti,et al. Role of phytochemicals in the management of metabolic syndrome. , 2016, Phytomedicine : international journal of phytotherapy and phytopharmacology.
[40] A. Sahebkar,et al. Lipoprotein(a) and inflammation: A dangerous duet leading to endothelial loss of integrity , 2017, Pharmacological research.
[41] I. Pećin,et al. Alirocumab: targeting PCSK9 to treat hypercholesterolemia. , 2015, Drugs of Today.
[42] A. Sahebkar,et al. Tibolone decreases Lipoprotein(a) levels in postmenopausal women: A systematic review and meta-analysis of 12 studies with 1009 patients. , 2015, Atherosclerosis.
[43] T. Santoso,et al. The effect of curcumin on lipid level in patients with acute coronary syndrome. , 2008, Acta medica Indonesiana.
[44] A. Sahebkar,et al. Curcuminoids Modulate Pro‐Oxidant–Antioxidant Balance but not the Immune Response to Heat Shock Protein 27 and Oxidized LDL in Obese Individuals , 2013, Phytotherapy research : PTR.
[45] Y. Li,et al. Curcuminoids exert glucose-lowering effect in type 2 diabetes by decreasing serum free fatty acids: a double-blind, placebo-controlled trial. , 2013, Molecular nutrition & food research.
[46] A. Sahebkar. A systematic review and meta-analysis of randomized controlled trials investigating the effects of curcumin on blood lipid levels. , 2014, Clinical nutrition.
[47] P. Kolh,et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). , 2011, European heart journal.
[48] M. Banach,et al. Effects of curcumin on HDL functionality , 2017, Pharmacological research.
[49] Y. Panahi,et al. A randomized controlled trial on the anti-inflammatory effects of curcumin in patients with chronic sulphur mustard-induced cutaneous complications , 2012, Annals of clinical biochemistry.
[50] A. Hoes,et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. , 2016, European heart journal.
[51] B. Aggarwal,et al. Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature. , 2008, Biochemical pharmacology.
[52] Ž. Reiner,et al. Effect of extended-release niacin on plasma lipoprotein(a) levels: A systematic review and meta-analysis of randomized placebo-controlled trials. , 2016, Metabolism: clinical and experimental.